Medico Remedies reported a 30% year-on-year increase in net profit after tax to ₹1,311.5 crore for FY26. Revenue from operations grew by 37% to ₹20,637.7 crore, reflecting strong demand across its pharmaceutical formulations portfolio.

The company has scheduled its 32nd Annual General Meeting for Tuesday, September 22, 2026, at 4:00 pm. The meeting will be conducted through video conferencing or other audio-visual means. Shareholders on record as of Friday, August 21, 2026, will be eligible to vote and attend.

Financial Performance

Total income for the financial year ended March 31, 2026, stood at ₹21,231.1 crore, up from ₹15,363.0 crore in the previous year. Total expenses rose to ₹19,425.1 crore from ₹14,012.6 crore. Profit before tax increased to ₹1,806.0 crore from ₹1,350.4 crore.

Other income contributed ₹593.4 crore to total income, compared to ₹268.9 crore in FY25. This increase was primarily driven by foreign exchange gains of ₹579.0 crore.

Corporate Governance and AGM Details

The register of members and share transfer books will remain closed from September 16, 2026, to September 22, 2026. The company issued the intimation on August 29, 2026, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key agenda items for the AGM include:

• Adoption of audited financial statements for FY26.
• Re-appointment of Mr. Haresh Kapurlal Mehta as Chairman and Whole-Time Director.
• Re-appointment of Mr. Rishit Mehta as Whole-Time Director.
• Increase in remuneration for Mr. Harshit Mehta, Managing Director.

What the Numbers Show

The significant rise in other income, largely due to foreign exchange gains, indicates that currency fluctuations played a material role in boosting the bottom line alongside operational revenue growth. While revenue expanded by nearly 37%, the net profit margin remained stable at approximately 6.4%, suggesting that cost structures scaled proportionately with sales volume.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE630Y01024/6ee8cd50-0130-4b9b-a930-31a0db48768e.pdf

Medico Remedies has secured a confirmed work order valued at $1.41 million (approximately ₹13.38 crore) from PROMESE/CAL (Programa de Medicamentos Esenciales y Central de Logística), a government entity in the Dominican Republic. The scope of work includes the supply of tablets, capsules, and dry syrups. The filing specifies an execution timeline of three months from the order date of August 5, 2026. This is classified as a confirmed order (TYPE A), meaning revenue recognition can begin upon shipment or delivery as per accounting standards.

Order Details

The following table summarises the key parameters of this order:

Order in Financial Context

The $1.41 million (₹13.38 crore) order represents a significant addition to the company's near-term pipeline, particularly given the absence of any disclosed order wins in the preceding three fiscal quarters. The total disclosed order book currently consists solely of this single transaction, as no other orders were recorded in the recent tracking window. For a microcap pharmaceutical player, international government contracts offer higher margin potential compared to domestic generic competition, provided logistics and regulatory compliance are managed efficiently.

Company Order Track Record

The company has not disclosed any order wins in the last three fiscal quarters, making this the first recorded inflow in the current tracking period. This suggests a potential restart or acceleration in order booking activity after a period of silence. The current order size of ₹13.38 crore serves as a new baseline for evaluating future deal sizes, as there is no recent historical average to compare against.

Revenue Growth and Execution Quality

The company's standalone revenue growth has shown positive momentum over the last five years, with FY25 growth at +4.50% following +17.30% in FY23. Profit growth has been even more robust, reaching +21.70% in FY25. These historical trends suggest that when orders are executed, they have translated into improving profitability. The current order from the Dominican Republic aligns with this trajectory of expanding international presence, which has been a key driver of past revenue acceleration.

Key Observations

• Order restart: First disclosed order win in the last three fiscal quarters, signaling renewed activity in the sales pipeline.
• International exposure: Contract awarded by a government entity in the Dominican Republic, diversifying geographic risk away from domestic markets.
• Execution timeline: The three-month delivery window requires rapid mobilization of manufacturing and logistics resources.
• Valuation check (as of 05 Aug 2026): P/E of 30.90x against ROCE of 23.33%. (P/E is price-derived and will change; ROCE is from audited financials)